An Open-label Study to Characterize the Pharmacokinetics and Safety of Oxycodone Hydrochloride q12h Controlled-Release (ORF) Tablets in Pediatric Patients Aged 6 to 16 Years Inclusive, Who Require Opioid Analgesia. Protocol No. OTR1020.


The purpose of this study was to characterize the pharmacokinetics and safety of ORF tablets in pediatric patients aged 6 to 16 years, inclusive.

Status: Completed
Funding: Purdue Pharma, L.P. sourced funding through PRA Health Sciences
Category: Research